KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Shares Outstanding (2016 - 2026)

Pacific Biosciences Of California has reported Shares Outstanding over the past 16 years, most recently at $302.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.56% year-over-year to $302.0 million; the TTM value through Dec 2025 reached $302.0 million, up 2.56%, while the annual FY2025 figure was $302.0 million, 2.56% up from the prior year.
  • Shares Outstanding for Q4 2025 was $302.0 million at Pacific Biosciences Of California, roughly flat from $301.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $302.0 million in Q4 2025 and troughed at $11.2 million in Q3 2021.
  • A 5-year average of $243.7 million and a median of $254.4 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: crashed 93.77% in 2021 and later skyrocketed 1914.42% in 2022.
  • Year by year, Shares Outstanding stood at $221.0 million in 2021, then increased by 2.5% to $226.5 million in 2022, then increased by 18.21% to $267.7 million in 2023, then increased by 9.96% to $294.4 million in 2024, then rose by 2.56% to $302.0 million in 2025.
  • Business Quant data shows Shares Outstanding for PACB at $302.0 million in Q4 2025, $301.9 million in Q3 2025, and $300.3 million in Q2 2025.